2.51
Annexon Inc Borsa (ANNX) Ultime notizie
Annexon Inc. Stock Analysis and ForecastOutperformance with explosive growth - PrintWeekIndia
Why Annexon Inc. stock attracts strong analyst attentionProven Trading Plan - Newser
How Annexon Inc. stock performs during market volatilityFree Predictions - Newser
Annexon Announces Completion of Enrollment in Pivotal Phase - GlobeNewswire
Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy - Ophthalmology Times
Annexon completes enrollment in Phase 3 ARCHER II trial - TipRanks
Annexon completes enrollment for phase 3 dry AMD therapy trial - Investing.com Australia
Annexon, Inc. Completes Enrollment of Phase 3 ARCHER II Trial for Vonaprument, Targeting Vision Preservation in Dry AMD with Geographic Atrophy - Nasdaq
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy - Yahoo Finance
What analysts say about Annexon Inc. stockBreakout portfolio performance - Autocar Professional
Is Annexon Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
What drives Annexon Inc. stock priceRapidly expanding wealth - jammulinksnews.com
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - 富途牛牛
Is Annexon Inc. stock a growth or value playHigh Reward Risk Balanced Trading - Newser
Annexon Inc (ANNX) Stock: A Comprehensive 52-Week Review - investchronicle.com
Annexon EVP Yednock sells $2.9k in shares By Investing.com - Investing.com South Africa
Annexon EVP Yednock sells $2.9k in shares - Investing.com Australia
What makes Annexon Inc. stock price move sharplyTop Performing Stocks - Newser
Annexon: Lead GBS Therapy Stokes Near Term Potential (NASDAQ:ANNX) - Seeking Alpha
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):